Republic Airways Holdings Inc (RJET) Peer Comparison
$17.68
As on 08-Sep-2026 16:00EDT
Market cap
$839 Mln
Revenue (TTM)
$1,653 Mln
P/E Ratio
11.9
P/B Ratio
0.6
Div. Yield
0 %
| Republic Airways Holdings Inc (RJET) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
839 | 9,571 | 1,105 | 892 | 8 |
Revenue ($ Mln) |
1,653 | 5,371 | 73 | 208 | -- |
Net Profit ($ Mln) |
48.98 | -169.00 | 36.72 | 52.16 | -10.47 |
Net Margin (%) |
2.96 | -3.15 | 50.13 | 25.13 | -- |
RoE (%) |
3.61 | -1.85 | 11.69 | 30.61 | -130.80 |
Price to Earnings |
11.87 | -- | 28.19 | 17.55 | -- |
Price-To-Book |
0.58 | 1.11 | 2.85 | 4.41 | 1.47 |
Income Statement ($ Mln)
| Republic Airways Holdings Inc (RJET) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1,676.50 | 5,355.00 | 34.76 | 148.47 | 0.00 |
|
Cost of Revenue
|
1,210.50 | 4,529.00 | 21.28 | 73.46 | -- |
|
Gross Profit
|
466.00 | 826.00 | 13.48 | 75.02 | -- |
|
Operating Expenses
|
250.60 | 574.00 | 7.64 | 20.76 | 4.24 |
|
Operating Profit (EBIT)
|
215.40 | 252.00 | 5.84 | 54.26 | -4.24 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
113.40 | -115.00 | 29.60 | 54.70 | -4.23 |
|
Provision for Tax
|
37.20 | -2.00 | 9.27 | 20.96 | -- |
|
Profit after Tax (Net Income)
|
76.20 | -98.00 | 20.33 | 33.74 | -4.23 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| Republic Airways Holdings Inc (RJET) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
1,328.50 | 8,246.00 | 233.96 | 150.73 | 11.22 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
1,373.80 | 8,394.00 | 151.17 | 28.86 | 0.22 |
|
Current Liabilities
|
574.30 | 1,548.00 | 32.88 | 28.85 | 0.14 |
|
Total Liabilities
|
3,276.60 | 19,185.00 | 418.01 | 208.45 | 11.58 |
Assets ($ Mln)
| Republic Airways Holdings Inc (RJET) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
2,735.90 | 17,946.00 | 393.79 | 96.72 | 0.35 |
|
Current Assets
|
540.70 | 1,239.00 | 24.22 | 111.72 | 11.23 |
|
Total Assets
|
3,276.60 | 19,185.00 | 418.01 | 208.45 | 11.58 |
|
Total Debt*
|
1,225.30 | 8,657.00 | 141.00 | 0.07 | 0.35 |
|
Net Current Assets
|
-33.60 | -309.00 | -8.66 | 82.87 | 11.09 |
Cashflow ($ Mln)
| Republic Airways Holdings Inc (RJET) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
322.00 | 943.00 | 16.95 | 52.98 | -10.48 |
|
Cash Flow from Investing Activities
|
-350.90 | -1,067.00 | -159.46 | -20.34 | -- |
|
Cash from Financing Activities
|
54.70 | 14.00 | 144.84 | 30.07 | 15.31 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Republic Airways Holdings Inc (RJET) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
3.17 | -0.60 | 6.94 | 29.00 | -70.02 |
|
ROE (%)
|
6.23 | -1.16 | 9.13 | 29.64 | -72.09 |
|
ROA (%)
|
2.52 | -0.52 | 6.27 | 21.39 | -69.85 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
4.55 | -1.83 | 58.49 | 22.72 | -- |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Republic Airways Holdings Inc (RJET) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.14 | 0.00 | 1.89 | 0.61 | -- |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
17.96 | 85.24 | 930.56 | 76.17 | -1,068.75 |
|
EPS Growth (%)
|
-0.92 | 0.85 | 22.18 | 0.56 | -10.44 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Republic Airways Holdings Inc (RJET) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
10.27 | -81.43 | -- | 15.37 | -0.11 |
|
Price / Book Value
|
0.59 | 0.97 | -- | 3.44 | 0.04 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
5.70 | 15.81 | -- | 6.90 | 0.99 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Republic Airways Holdings Inc (RJET) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.92 | 1.05 | 0.60 | 0.00 | 0.03 |
|
Short term debt to equity ratio
|
0.16 | 0.02 | -- | 0.00 | 0.01 |
|
Current Ratio
|
0.94 | 0.80 | 0.74 | 3.87 | 81.93 |
|
Quick Ratio
|
0.79 | 0.71 | -- | 2.86 | -- |
|
Interest Coverage
|
2.87 | 0.57 | 3.43 | 55.05 | -493.92 |
Operating Efficiency Ratios
| Republic Airways Holdings Inc (RJET) | Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
6.33 | 16.73 | 27.70 | 1.38 | -- |
|
Asset Turnover
|
0.55 | 0.28 | 0.11 | 0.94 | 0.00 |
|
Receivable days
|
17.21 | 58.73 | 52.53 | 2.99 | -- |
|
Inventory Days
|
22.86 | 13.39 | -- | 100.11 | -- |
|
Payable days
|
27.62 | 93.39 | 35.28 | 59.08 | -- |
|
Cash Conversion Cycle
|
12.44 | -21.28 | -- | 44.01 | -- |